Coherus (CHRS) CFO covers RSU tax bill with 1,715 shares

Rhea-AI Filing Summary

Coherus Oncology’s Chief Financial Officer reports a small tax-related share withholding. On January 20, 2026, 1,715 shares of Coherus Oncology, Inc. common stock were automatically withheld by the company at $1.55 per share to cover tax liabilities tied to vesting restricted stock units. This was reported under transaction code F, which typically reflects tax withholding rather than an open‑market trade.

After this withholding, the CFO directly beneficially owned 21,236 shares of Coherus common stock. The footnote clarifies that no shares were sold by the reporting person; the shares were retained by the issuer to satisfy taxes due on equity compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMichael Bryan J

(Last) (First) (Middle)

C/O COHERUS ONCOLOGY, INC.

333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		F		1,715(1)	D	$1.55	21,236	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.

	/s/ Bryan J. McMichael	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Coherus Oncology (CHRS) report for its CFO?

The Chief Financial Officer of Coherus Oncology, Inc. (CHRS) reported a transaction on January 20, 2026 in which 1,715 shares of common stock were automatically withheld by the company to cover tax liabilities related to vesting restricted stock units.

Was the Coherus (CHRS) CFO’s Form 4 transaction an open-market sale?

No. The filing states that the 1,715 shares were automatically withheld by the issuer to pay tax liabilities from RSU vesting, and explicitly notes that no shares were sold by the reporting person in this transaction.

How many Coherus (CHRS) shares does the CFO own after the reported transaction?

After the tax withholding transaction, the Coherus Chief Financial Officer beneficially owned 21,236 shares of Coherus Oncology, Inc. common stock in direct ownership.

What does transaction code "F" mean in the Coherus (CHRS) Form 4 filing?

In this filing, code "F" indicates shares were withheld by the issuer to satisfy tax obligations associated with equity compensation, rather than a discretionary market purchase or sale by the insider.

At what price were the Coherus (CHRS) shares withheld for the CFO’s tax obligations?

The 1,715 withheld shares of Coherus common stock were valued at $1.55 per share for the purpose of covering the related tax liability on the vesting restricted stock units.

What is the reporting person’s role at Coherus Oncology (CHRS) in this Form 4?

The reporting person, Bryan J. McMichael, is identified as the Chief Financial Officer of Coherus Oncology, Inc., and filed the Form 4 as a single reporting person.